GRAPHITE BIO, INC.

Profile

Company Names

GRAPHITE BIO, INC.

Addresses

279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO, CA 94080

Phone Numbers

(650) 484-0886

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2019

State Incorporated:

DELAWARE

Total Amount Raised:

$150,749,985.00

Number of Funding Rounds:

1
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
1
2021-03-11 
$150,749,985.00 
$150,749,985.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ABRAHAM 
 
BASSAN 
DIRECTOR
GRAPHITE BIO, INC.   |  CARGO THERAPEUTICS, INC.   |  SEPTERNA, INC.   |  SAMSARA OPPORTUNITY FUND, L.P.   |  RANI THERAPEUTICS HOLDINGS, INC.
JEREL 
 
DAVIS 
DIRECTOR
CHANRX CORP.   |  LAGUNA PHARMACEUTICALS, INC.   |  INCEPTION IBD, INC.   |  TRAVUS THERAPEUTICS, INC.   |  VERSANT VENTURE CAPITAL VI, L.P.   |  MISTRAL THERAPEUTICS, INC.   |  VERSANT VOYAGEURS I FEEDER, L.P.   |  VERSANT VENTURE CAPITAL VII, L.P.   |  TURNSTONE BIOLOGICS CORP.   |  NORTHERN MOSAIC LP   |  VERSANT VOYAGEURS I, L.P.   |  VERSANT VOYAGEURS I PARALLEL, L.P.   |  CHINOOK THERAPEUTICS U.S., INC.   |  VENTUS THERAPEUTICS U.S., INC.   |  TENTARIX BIOTHERAPEUTICS, LP   |  RAYZEBIO, INC.   |  GRAPHITE BIO, INC.   |  VERSANT VANTAGE II, L.P.   |  VERSANT VOYAGEURS II, L.P.   |  VERSANT VOYAGEURS II (CANADA), L.P.   |  VERSANT VENTURE CAPITAL VIII, L.P.   |  VERSANT VENTURE CAPITAL VIII (CANADA), L.P.   |  SANTA ANA BIO, INC.   |  VERSANT VOYAGEURS III, L.P.   |  VERSANT VOYAGEURS III (CANADA), L.P.   |  VERSANT VANTAGE III, L.P.   |  VERSANT VANTAGE III (CANADA), L.P.   |  VERSANT VENTURE CAPITAL IX, L.P.   |  VERSANT VENTURE CAPITAL IX (CANADA), L.P.   |  FIREFLY BIO, INC.   |  VERSANT VENTURE CAPITAL SPV I (SAB), L.P.
PHILIP 
 
GUTRY 
EXECUTIVE OFFICER
KRONOS BIO, INC.   |  GRAPHITE BIO, INC.
JOE 
 
JIMENEZ 
DIRECTOR
GRAPHITE BIO, INC.
PERRY 
 
KARSEN 
DIRECTOR
AGIOS PHARMACEUTICALS INC   |  ALLIQUA, INC.   |  E-SCAPE BIO, INC.   |  ESCAPE BIO, INC.   |  JOUNCE THERAPEUTICS, INC.   |  GRAPHITE BIO, INC.
JOSH 
 
LEHRER 
EXECUTIVE OFFICER, DIRECTOR
GRAPHITE BIO, INC.   |  MAREA THERAPEUTICS, INC.
MATTHEW 
 
PORTEUS 
DIRECTOR
GRAPHITE BIO, INC.   |  KAMAU THERAPEUTICS, INC.
CARLO 
 
RIZZUTO 
DIRECTOR
VENATORX PHARMACEUTICALS, INC.   |  QUENTIS THERAPEUTICS, INC.   |  PANDION THERAPEUTICS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  GRAPHITE BIO, INC.   |  CENTURY THERAPEUTICS, INC.   |  858 THERAPEUTICS, INC.   |  JNANA THERAPEUTICS INC.   |  NEXO THERAPEUTICS, INC.   |  VERSANT VOYAGEURS III, L.P.   |  VERSANT VOYAGEURS III (CANADA), L.P.   |  VERSANT VANTAGE III, L.P.   |  VERSANT VANTAGE III (CANADA), L.P.   |  VERSANT VENTURE CAPITAL IX, L.P.   |  VERSANT VENTURE CAPITAL IX (CANADA), L.P.   |  PEP2TANGO THERAPEUTICS, INC.
MARIA GRAZIA 
 
RONCAROLO 
DIRECTOR
GRAPHITE BIO, INC.
KATHERINE 
 
STULTZ 
EXECUTIVE OFFICER
GRAPHITE BIO, INC.   |  OCELOT BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2021-03-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2021-03-11 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#